Key facts
- It has raised $106.0M across 2 recorded rounds; the latest was Early Stage VC ($14.0M) in May 2023.
- Notable investors include Norwest, Novo Holdings, Deerfield Management, Platanus, 4BIO Capital — 7 tracked in total.
- Ray Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently May 2023 ($14.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ray Therapeutics
Funding rounds
2 roundsAbout Ray Therapeutics
Developer of optogenetic gene therapies designed for vision restoration purposes. The company utilizes bioengineered light-sensitive proteins delivered to targeted retinal cells through intravitreal injections to improve visual function, compatibility with various retinal blindness forms, enabling patients with severe retinal degeneration to regain sight, and lifelong effects from single treatments.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2021
- Employees
- 30
- Website
- raytherapeutics.com/
- Ownership
- Privately Held (backing)
Ray Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ray Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ray Therapeutics in its N-PORT filings yet. We sweep new filings monthly.